No Data
Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Jiangsu Nhwa Pharmaceutical (002262.SZ): Fentanyl Active Pharmaceutical Ingredient has not been exported to the USA.
On February 13th, according to Gelonghui, Jiangsu Nhwa Pharmaceutical (002262.SZ) stated on the investor interaction platform that the company's production and operation activities are running normally, and the operation situation is good. The company will make every effort to accelerate the research and development and introduction of new products, striving to launch new products as soon as possible. At the same time, actively responding to the dynamic changes in the market operating environment, continuously increasing efforts to explore the market, steadily improving the company's sales performance, and creating more value to return to the broad investors. The company's Active Pharmaceutical Ingredient of fentanyl has not been exported to the USA.
Jiangsu Nhwa Pharmaceutical (002262.SZ): Its invested company Jiangsu Haoxinqing is increasing its capital.
Gelonghui, on February 10, announced that Jiangsu Nhwa Pharmaceutical (002262.SZ) has recently signed agreements with four investment Institutions: Xuzhou Chuantou Industry Investment Fund Partnership (Limited Partnership) (referred to as "Xuzhou Chuantou"), Qingdao Xinhong Venture Capital Partnership (Limited Partnership) (referred to as "Xinhong Venture Capital"), Zhongtai Noyuan (Xiamen) Venture Capital Partnership (Limited Partnership) (referred to as "Zhongtai Noyuan"), and Nanjing United Future Health Industry Investment Partnership (Limited Partnership) (referred to as "United Future").
With EPS Growth And More, Jiangsu Nhwa Pharmaceutical (SZSE:002262) Makes An Interesting Case
Jiangsu Nhwa Pharmaceutical's (SZSE:002262) Five-year Earnings Growth Trails the Splendid Shareholder Returns
Jiangsu Nhwa Pharmaceutical (002262.SZ) has obtained the "Pharmaceutical Registration Certificate" for Hydrobromide Vortioxetine Tablets.
Jiangsu Nhwa Pharmaceutical (002262.SZ) announced that the company recently obtained approval from the National Medical Products Administration.
Little Excitement Around Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings
